What is Aura Biosciences, Inc.'s depreciation?

Aura Biosciences, Inc. (AURA) reported depreciation of $274K in Q1 2026.

How has Aura Biosciences, Inc.'s depreciation changed year-over-year?

Aura Biosciences, Inc.'s depreciation decreased by 5.8% year-over-year, from $291K to $274K.

Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s depreciation has grown at a 9.3% compound annual growth rate (CAGR), from $815K to $1.16M.

Merck & Co.MRK

——

Summit TherapeuticsSMMT

——

Operating income-$34.9M-20.1%

Net income-$33.7M-22.6%

EPS (diluted)-$0.50+9.1%

Cash & equivalents$84.8M+122%

Total debt$17.0M-7.9%

Total equity$107.2M-16.2%

Total assets$137.7M-11.4%

Operating cash flow-$29.9M-28.0%

CapEx$102.0K-45.5%

Free cash flow-$30.0M-27.4%

Market cap$709.23M+89.4%

Enterprise value$641.43M+80.8%

Return on equity-95.6%+222pp

Debt / equity0.2×0.0×

Current ratio7.1×-4.0×

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Aura Biosciences, Inc.'s depreciation?: Aura Biosciences, Inc. (AURA) reported depreciation of $274K in Q1 2026.
How has Aura Biosciences, Inc.'s depreciation changed year-over-year?: Aura Biosciences, Inc.'s depreciation decreased by 5.8% year-over-year, from $291K to $274K.
What is the long-term trend for Aura Biosciences, Inc.'s depreciation?: Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s depreciation has grown at a 9.3% compound annual growth rate (CAGR), from $815K to $1.16M.